11/13/2024 8:04 AM | Adaptimmune Therapeutics (Subject) Matrix Capital Management Company, LP (Filed by)
| Form SC 13G/A | |
11/13/2024 8:10 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/01/2024 4:00 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
09/23/2024 3:15 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/12/2024 6:23 AM | Adaptimmune Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
08/12/2024 6:05 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/02/2024 6:00 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
|
07/16/2024 3:30 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/15/2024 6:39 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/15/2024 6:14 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/14/2024 6:34 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
04/22/2024 4:15 PM | Adaptimmune Therapeutics (Filer)
| Form ARS | |
04/12/2024 7:05 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
04/11/2024 7:00 AM | Adaptimmune Therapeutics (Filer)
| Form DEF 14A | |
04/02/2024 7:38 PM | Adaptimmune Therapeutics (Subject) New Enterprise Associates 14, L.P. (Filed by)
| Form SC 13D/A | |
04/01/2024 7:01 AM | Adaptimmune Therapeutics (Filer)
| Form PRE 14A | |
03/26/2024 10:59 AM | Adaptimmune Therapeutics (Subject) EcoR1 Capital, LLC (Filed by)
| Form SC 13G/A | |
03/26/2024 11:00 AM | Adaptimmune Therapeutics (Issuer) EcoR1 Capital, LLC (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
03/06/2024 6:05 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/06/2024 6:12 AM | Adaptimmune Therapeutics (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
02/27/2024 7:13 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/31/2024 4:07 PM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/30/2024 4:26 PM | Adaptimmune Therapeutics (Subject) EcoR1 Capital, LLC (Filed by)
| Form SC 13G | |
01/29/2024 10:52 AM | Adaptimmune Therapeutics (Subject) BAILLIE GIFFORD & CO (Filed by)
| Form SC 13G/A | |
01/17/2024 4:30 PM | Adaptimmune Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/17/2024 4:30 PM | Adaptimmune Therapeutics (Issuer) Bertrand William C JR (Reporting) Bertrand William C JR (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/17/2024 4:30 PM | Adaptimmune Therapeutics (Issuer) Adaptimmune Therapeutics (Issuer) Lunger John (Reporting) Lunger John (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/17/2024 4:31 PM | Adaptimmune Therapeutics (Issuer) Adaptimmune Therapeutics (Issuer) Norry Elliot (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/17/2024 4:31 PM | Adaptimmune Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/17/2024 4:31 PM | Adaptimmune Therapeutics (Issuer) Rawcliffe Adrian (Reporting) Rawcliffe Adrian (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/17/2024 4:00 PM | Adaptimmune Therapeutics (Issuer) Rawcliffe Adrian (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/17/2024 4:01 PM | Adaptimmune Therapeutics (Issuer) Norry Elliot (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/17/2024 4:01 PM | Adaptimmune Therapeutics (Issuer) Wood Gavin (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/17/2024 4:01 PM | Adaptimmune Therapeutics (Issuer) TAYTON-MARTIN HELEN KATRINA (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/17/2024 4:02 PM | Adaptimmune Therapeutics (Issuer) Brewer Joanna Elizabeth (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/17/2024 4:02 PM | Adaptimmune Therapeutics (Issuer) Lunger John (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/17/2024 4:03 PM | Adaptimmune Therapeutics (Issuer) Hege Kristen (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/17/2024 4:03 PM | Adaptimmune Therapeutics (Issuer) Bertrand William C JR (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/17/2024 4:06 PM | Adaptimmune Therapeutics (Issuer) Behbahani Ali (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/04/2024 6:46 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
12/06/2023 6:13 AM | Adaptimmune Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
Breaking News: Tesla headed to $500… (Ad) That headline hit late last night…and the rally has begun
Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. |